Identification of PPARgamma partial agonists of natural origin (I): development of a virtual screening procedure and in vitro validation
about
Pharmacophore Models and Pharmacophore-Based Virtual Screening: Concepts and Applications Exemplified on Hydroxysteroid DehydrogenasesIdentification of PPARgamma partial agonists of natural origin (II): in silico prediction in natural extracts with known antidiabetic activityIdentification of novel multitargeted PPARα/γ/δ pan agonists by core hopping of rosiglitazoneIdentification of a novel selective agonist of PPARγ with no promotion of adipogenesis and less inhibition of osteoblastogenesis.Pharmacophore modeling improves virtual screening for novel peroxisome proliferator-activated receptor-gamma ligands.A new dawn for the use of thiazolidinediones in cancer therapy.The potential role of in silico approaches to identify novel bioactive molecules from natural resources.Molecular modelling study of the PPARγ receptor in relation to the mode of action/adverse outcome pathway framework for liver steatosis.Structural basis for PPAR partial or full activation revealed by a novel ligand binding mode.KDT501, a derivative from hops, normalizes glucose metabolism and body weight in rodent models of diabetesProbing the intermolecular interactions of PPARγ-LBD with polyunsaturated fatty acids and their anti-inflammatory metabolites to infer most potential binding moieties.Decoys Selection in Benchmarking Datasets: Overview and Perspectives.Development of an In Vitro Screening Platform for the Identification of Partial PPARγ Agonists as a Source for Antidiabetic Lead Compounds
P2860
Q26772046-6EBBEB09-9CEA-462B-99F7-CCADB7B8FA91Q28486003-1719323B-8E8C-4EF9-9B5F-464549210701Q34511474-D80F9018-F798-43EB-B770-FFE3447EBB30Q35237706-3BB686AD-000A-47B6-89A1-B23CE8ADDE9FQ35395528-5431566D-5C1A-4D40-9B09-1BEA33C0CF5FQ38193545-DFE1FC03-A967-4295-877D-F81514292258Q38637348-82FB200E-FF84-44CD-803E-B2E5B7E0703AQ40709802-E3AA7D78-D402-4478-B39C-6DF77A8D22E4Q41343506-D1104006-7B34-4749-BDE5-34C8ADB5F897Q41836836-2ED0D6D7-30A1-4300-9B48-1C71EC23DBE9Q42148203-3863C35D-2EF0-4B4E-8DE4-7BCA9C3619F4Q49221491-393BE994-BC32-43C1-916D-02716E38C72FQ58696993-BD1E4B00-706D-4B2B-8C2A-3B9FD8A3EB1E
P2860
Identification of PPARgamma partial agonists of natural origin (I): development of a virtual screening procedure and in vitro validation
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Identification of PPARgamma pa ...... cedure and in vitro validation
@ast
Identification of PPARgamma pa ...... cedure and in vitro validation
@en
Identification of PPARgamma pa ...... cedure and in vitro validation
@nl
type
label
Identification of PPARgamma pa ...... cedure and in vitro validation
@ast
Identification of PPARgamma pa ...... cedure and in vitro validation
@en
Identification of PPARgamma pa ...... cedure and in vitro validation
@nl
prefLabel
Identification of PPARgamma pa ...... cedure and in vitro validation
@ast
Identification of PPARgamma pa ...... cedure and in vitro validation
@en
Identification of PPARgamma pa ...... cedure and in vitro validation
@nl
P2093
P2860
P50
P3181
P1433
P1476
Identification of PPARgamma pa ...... cedure and in vitro validation
@en
P2093
Anna Castell-Auví
Cristina Valls
Esther Sala
Laura Guasch
Lidia Cedó
Markus Muehlbacher
Miquel Mulero
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0050816
P407
P577
2012-01-01T00:00:00Z